Drug Discovery

Mediar and Ono Pharmaceutical to develop fibro-inflammatory treatments

Mediar Therapeutics has announced a collaboration and option agreement with Ono Pharmaceutical to develop new treatments for fibro-inflammatory diseases.

Evotec and Odyssey collaborate on AI-enabled R&D

Evotec and Odyssey Therapeutics have announced a strategic AI-enabled research and development (R&D) partnership to explore new treatments for autoimmune and inflammatory diseases.

Schrödinger and BMS expand partnership to deploy AI for drug discovery

Schrödinger has entered a strategic agreement with Bristol Myers Squibb (BMS) to integrate its AI-based co-scientist platform Bunsen into BMS’s research operations.

Phylo and Chugai collaborate to deploy AI platform in drug discovery

Phylo has entered a collaboration with Japan-based company Chugai Pharmaceutical to implement Biomni Lab, an agentic AI platform designed for biomedical research, within the latter’s drug discovery operations.

Amgen’s Repatha receives positive CHMP opinion for broader cardiovascular use

Amgen has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for Repatha (evolocumab) supporting its broader use prior to a first heart attack or stroke.

Eisai and CORE Biomedicine agree on global licence for oncology pipeline

Japanese company Eisai has entered an exclusive global licensing agreement with CORE Biomedicine for several preclinical oncology programmes.

BioMarin and n-Lorem partner on early research for ReNU syndrome therapy

BioMarin Pharmaceutical and n-Lorem Foundation have entered an early-stage research collaboration and exclusive global licence agreement to develop an investigational antisense oligonucleotide (ASO) therapy for ReNU syndrome.

Biointron introduces RushData platform for AI-driven antibody discovery

Biointron Biological has launched RushData, a new platform to support the process of antibody discovery for pharmaceutical and biotechnology companies employing AI and machine learning (ML).

Kyowa Kirin EMEA’s Crysvita approved by EC for infants with XLH

Kyowa Kirin subsidiary Kyowa Kirin EMEA has received approval from the European Commission (EC) to expand the use of Crysvita (burosumab) for treating X-linked hypophosphataemia (XLH) in infants aged one month to one year across the EU and European Economic Area.